Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 8/20 | 0.38 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 4/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20359891 | 0.89 | BTK (0.37) | BTKLCKCNR2KCNH2MCHR1 | |
| SCHEMBL20359888 | 0.89 | BTK (0.37) | BTKLCKCNR2KCNH2MCHR1 | |
| SCHEMBL20359566 | 0.87 | BTK (0.38) | BTKLCKCNR2KCNH2MCHR1 | |
| SCHEMBL20358717 | 0.83 | MAPT (0.35) | BTKCNR2MCHR1ACACB | |
| SCHEMBL20358535 | 0.77 | BTK (0.47) | BTKLCK | |
| SCHEMBL20358538 | 0.77 | BTK (0.47) | BTKLCK | |
| SCHEMBL20358509 | 0.74 | BTK (0.44) | BTKLCKKCNH2 | |
| SCHEMBL20358512 | 0.74 | BTK (0.44) | BTKLCKKCNH2 | |
| SCHEMBL20365271 | 0.74 | BTK (0.52) | BTKLCK | |
| SCHEMBL20359472 | 0.74 | BTK (0.44) | BTKLCKKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | PHARMACYCLICS LLC (US) | 2018-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180194762-A1 | PYRAZOLO[3,4-b]PYRIDINE AND PYRROLO[2,3-b]PYRIDINE INHIBITORS OF BRUTON'S TYROSINE KINASE | BTK, SYK, LCK | BTK 1/4885LCK 3/4885CNR2 1439/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.